Adefovir Dipivoxil Tablets — Competitive Intelligence Brief

Adefovir Dipivoxil Tablets (Adefovir Dipivoxil Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor. Area: Virology / Hepatology.

marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase and DNA polymerase Virology / Hepatology Small molecule

Target snapshot

Adefovir Dipivoxil Tablets (Adefovir Dipivoxil Tablets) — Sun Yat-sen University. Adefovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adefovir Dipivoxil Tablets TARGET	Adefovir Dipivoxil Tablets	Sun Yat-sen University	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase and DNA polymerase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
tenofovir disproxil fumarate/emtricitabine	tenofovir disproxil fumarate/emtricitabine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
Adefovir dipivoxil (adefovir)	Adefovir dipivoxil (adefovir)	Merck Sharp & Dohme LLC	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase / DNA polymerase
Biktarvy Tab	Biktarvy Tab	Southampton Healthcare, Inc.	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase, CCR5 co-receptor
Tenofovir/Emtricitabine	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Telbivudine, Adefovir dipivoxil	Telbivudine, Adefovir dipivoxil	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus DNA polymerase / reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor class)

1. GlaxoSmithKline · 2 drugs in this class
2. IlDong Pharmaceutical Co Ltd · 1 drug in this class
3. Bristol-Myers Squibb · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
6. Sun Yat-sen University · 1 drug in this class
7. Jiangxi Kvvit Pharmaceutical Co., Ltd. · 1 drug in this class